As described in our results, mutation that only occurs in embryonal carcinoma (B3GNT8, CAPN7, FAT4, GRK1, TACC2 and TRAM1L1) or seminoma (KIT, KARS and NRAS) may be valuable molecular markers and therapeutic targets that need to be considered clinically. Here, NRAS is linked to embryonal carcinoma.